Eupraxia 制药 EPRX

On February 18, 2025, the Company announced the appointment of Alex Rothwell as the Company's new Chief Financial Officer.

Dr. Helliwell is the Co-founder and CEO of Eupraxia Pharmaceuticals. A board-certified Cardiac Anesthesiologist, he previously maintained a busy quaternary clinical and academic practice with a focus on cardiac transplantation and held a double tenure as President of the Anesthesiologists of BC. Dr. Helliwell's experience in the operating room and ICU instilled an appreciation for the value of precision drug delivery to achieve successful patient outcomes. This led him to create Eupraxia Pharmaceuticals, a company developing precision medicines in areas of high unmet medical need. In 2021, Eupraxia became the first biotech to successfully list exclusively on the Toronto Stock Exchange in almost 20 years. The company's lead product candidate - a long-acting corticosteroid to treat osteoarthritis pain - is currently in Phase 2 clinical development. Dr. Helliwell has also applied precision delivery to the medical device space. As Co-founder and CEO of Accuro Technologies, he invented Arthrotap - a medical device to improve the accuracy of intra-articular injections. After successfully transacting on Accuro, he moved on to serve as Chair of the Board for Guidestar Medical Devices - a company focused on precision medicines delivery for the epidural space.

Dr. Amanda Malone, Principal Occupation or Business or Employment in the Past Five Years - Chief Scientific Officer and Chief Operating Officer, Eupraxia Pharmaceuticals Inc. (Sep 2012 - Present).

Dr. Mark Kowalski was appointed Chief Medical Officer of the Company on May 18, 2023.

Mr. Paul Brennan was appointed Chief Business Officer of the Company on November 1, 2022.

Dr. Simon Pimstone is a physician-scientist-and experienced board chair whose leadership spans biotechnology, healthcare policy, clinical research, and national innovation initiatives. Dr. Simon Pimstone is the founder and Chief Executive Officer of XYON Health Inc., a privately held Canadian company delivering innovative healthcare solutions for men and women with hair loss. Dr. Pimstone has held management, board, and advisory roles with organizations including Xenon Pharmaceuticals (Nasdaq: XENE), Alpha9 Oncology, Borealis Biosciences and Kokua Pharmaceuticals. He has also served on the boards of several industry and healthcare associations, including as former Chair of LifeSciences BC and the Providence Healthcare Research Trust, and as former Vice-Chair-of BIOTECanada. He has additionally chaired the Canadian federal government's State of the Nation Report. Dr. Pimstone has won several awards, namely Globe and Mail top 40 under 40, Don Rix Lifetime Achievement Award and Business in Vancouver top 40 under 40. At Eupraxia Pharmaceuticals, Dr. Pimstone serves as Chairman of the Board and is a member of the Compensation, Audit and Nomination & Governance Committees. He has served on the Board since 2013. Dr. Pimstone received his MD from the University of Cape Town (MBChB, 1991) and is an internal medicine specialist (FRCPC, UBC, 2001). Prior to his specialization, he trained as a clinical research fellow with the Department of Medical Genetics at the University of British Columbia and earned a PhD in cardiovascular genetics through the University of Amsterdam (1998). He also serves as a consultant physician at the UBC Medical and Cardiology Clinic at UBC Hospital in Vancouver. Dr. Pimstone has received a number of awards and is widely published.

John Montalbano is a global investment executive and the former Chief Executive Officer of RBC Global Asset Management, retiring in 2015 after leading the firm's growth to $370 billion in assets under management, placing it among the 50 largest asset managers worldwide at the time. Mr. Montalbano currently serves as a Director and Audit Chair of the Canada Pension Plan Investment Board, a Director of AbCellera Inc. (NASDAQ), a Director of Manulife, and as Chairman of White Crane Capital, a Vancouver-based hedge fund. He has also served as a Director of Aritzia Inc. At Eupraxia Pharmaceuticals, Mr. Montalbano serves as a director and contributes to governance oversight through his roles as Chair of the Audit Committee and as a member of the Nominating & Governance Committee. He has served on the Board since 2013. Mr. Montalbano has held several prominent civic and philanthropic leadership roles, including serving as Chair of the UBC Board of Governors, St. Paul's Foundation, and the Vancouver Police Foundation. He also co-founded the Take a Hike Youth at Risk Foundation and has held leadership positions with the Asia Pacific Foundation of Canada, the Rideau Hall Foundation, and Windmill Microlending. Mr. Montalbano holds the Chartered Financial Analyst (CFA) designation, a Bachelor of Commerce (Honours) from the University of British Columbia, and an Honorary Doctor of Letters from Emily Carr University of Art and Design.

Paul Geyer is a medtech founder-operator, investor, and executive with more than 30 years of experience building and scaling medical technology and digital health companies. He has led organizations through major growth phases, including an exit and a transition to a public company, and has built teams of more than 350 employees. Mr. Geyer is currently the Chief Investment Officer of Nimbus Synergies, a venture capital firm supporting British Columbia-based digital health companies. He retired as CEO of Nimbus Synergies and Discovery Parks Investments Ltd. in 2025 to focus on health technology investing and managing the Geyer Family Office. He is also an active mentor and angel investor in medical technology ventures. Mr. Geyer founded Mitroflow in 1991, growing it from nine to more than 125 employees before its sale in 1999. He later founded Medical Ventures (Neovasc), serving as CEO until 2008 and raising over $40 million in equity financing while completing three acquisitions. From 2009 to 2017, he was the founding CEO of LightIntegra Technology, developer of ThromboLux, a point-of-care device for assessing platelet quality. Since 2008, Mr. Geyer has supported entrepreneurs as a mentor, advisor, and board member, including as a Fellow of Creative Destruction Labs. He has also contributed to organizations such as BCTech, LifeSciences BC, Science World, the Vancouver General Hospital & UBC Hospital Foundation, and Junior Achievement BC. At Eupraxia Pharmaceuticals, Mr. Geyer serves as a director and is a member of the Audit Committee. He has served on the Board since 2013. He currently sits on the Boards of Montfort, Arbutus Medical, MetaOptima, and Stoko, and also serves on the Boards of the VGH Hospital Foundation and Junior Achievement BC, where he has frequently chaired Boards and Finance and Investment Committees. Mr. Geyer holds a BASc in Electrical Engineering, has completed programs in Biomedical Engineering and Venture Capital, and holds a Certified Director designation from UCLA. He recently retired as a Professional Engineer in British Columbia after more than 30 years of practice.

Dr. Wilmink is an Orthopaedic surgeon and partner in OrthoArizona where he is active in both the Operations Committee and Research Committee. Dr. Wilmink was an inventor of the muscle sparing anterior approach technique for hip replacements and currently lectures and teaches this technique to surgeons across the United States. In addition, Dr. Wilmink is a surgeon designer for NextStep Arthropedix and has brought two FDA approved hip replacement systems to the market and a total knee system coming to the clinical market in 2021. Dr. Wilmink is active in the Phoenix medical community sitting on the boards of OASIS Surgical Hospital and the Gateway Outpatient Surgical Center. Michael completed his undergraduate education at University of California at Los Angeles in Physiological Sciences and was a scholarship All American Water Polo player. Dr. Wilmink completed his Medical Degree and Orthopaedic Surgical Residency at UBC. Outside of the medical world, Dr. Wilmink was elected to be a Phoenix Thunderbird and collaborates with business leaders in the community to run and operate the Waste Management Phoenix Open PGA Golf Tournament.

Dr. Richard M. Glickman. Principal Occupation or Business or Employment in the Past Five Years - Chairman of the Board, enGene Inc. (October 2011 - Present), Chairman of the Board, ESSA Pharma Inc. (October 2010 - 2025), Co-founder and Executive Chairman (September 2013 - February 2014) and Chairman of the Board (February 2014 - April 2019) and Chief Executive Officer (February 2017 - April 2019), Aurinia Pharmaceuticals Inc., Venture Partner, Lumira Ventures (March 2016 - Present).

Mr. Joseph Freedman. Principal Occupation or Business or Employment in the Past Five Years - Chairman of the Board Director, Centre for Aging and Brain Health Innovation (2021 - Present), Director, Bridgemarq Real Estate Services (2020 - Present), Director, Total Containment Inc. (March 2022 - Present).

Ms. Amy Pott, Principal Occupation or Business or Employment in the Past Five Years: Global Chief Commercialization Officer, enGene (May 2025 - Present), Senior Vice President, Strategic Brand Marketing, Opthalmics and Rare Diseases, Astellas Pharma (April 2024- May 2025), Head of Commercial, Gene Therapies, Astellas Pharma (January 2021 - April 2024).

Mr. Robert B. Bazemore, Jr, Principal Occupation or Business or Employment in the Past Five Years: Lead Independent Director, Nuvation Bio, Inc. (2021 - Present), Director, Ardelyx, Inc. (2016 - Present), Director, Akari Therapeutics, Inc. (2024 - Present), Chief Executive Officer and Director, Epizyme, Inc. (2016 - 2021).